Journal of Cancer Metastasis and Treatment最新文献_第7页

Thymic carcinoma: review and update 胸腺癌:回顾与更新

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.185

K. Karlin, P. Michaels

引用次数: 3

Diffuse large B-Cell lymphoma: from novel molecular classifications to tailored targeted therapies 弥漫性大b细胞淋巴瘤:从新的分子分类到量身定制的靶向治疗

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.193

J. Lue, G. Nowakowski

引用次数: 0

Combined effects of oncolytic vaccinia virus and dendritic cells on the progression of melanoma B16-F10 in mice 溶瘤痘苗病毒和树突状细胞对小鼠黑色素瘤B16-F10进展的联合影响

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.195

E. Goncharova, Tatiana A. Gamburg, O. Markov, M. Zenkova

{"title":"Combined effects of oncolytic vaccinia virus and dendritic cells on the progression of melanoma B16-F10 in mice","authors":"E. Goncharova, Tatiana A. Gamburg, O. Markov, M. Zenkova","doi":"10.20517/2394-4722.2021.195","DOIUrl":"https://doi.org/10.20517/2394-4722.2021.195","url":null,"abstract":"Aim: We aimed to test the hypothesis that loading of dendritic cells (DCs) with both viral and tumor-specific antigens would enhance the efficacy antitumor DC-based therapy applied simultaneously with oncolytic virus. Methods: Vaccinia virus LIVP/GFP and melanoma B16-F10 were used in this study. DCs were pulsed with various combinations of viral and tumor-associated antigens. The maturation status of DCs was verified by expression of the markers CD80, CD86, and CCR7 and assessment of IL-6, TNF-α, and IL-12 secretion. The most efficient combination of antigens for DC loading was selected based on the analysis of the cytotoxic activity of T lymphocytes. Combination therapy using vaccinia virus LIVP/GFP and DCs pulsed with viral and tumor-specific antigens was administered to the B16-F10 melanoma/mouse C57Bl tumor model. Results: We found that loading of DCs with viral antigens, or with a combination of viral and tumor antigens, resulted in similar levels of expression of DC maturation markers. The maximal in vitro cytotoxicity against virus-infected and non-infected B16 melanoma cells exhibited T lymphocytes activated by DCs loaded with the heat inactivated lysate of vaccinia virus LIVP/GFP infected tumor cell. The results show that the combination of vaccinia virus LIVP/GFP and DCs loaded with both tumor and viral antigens inhibit tumor growth of B16-F10 murine melanoma by more than two-fold. Conclusions: Combination therapy with oncolytic vaccinia virus LIVP/GFP and tumor/virus antigen-loaded DCs limited the growth of established melanoma B16-F10, but no synergistic antitumor effects were observed. We propose that optimization of the therapy regimen could enhance the efficiency of combination therapy.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67651945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical route and pathological risk factors in early cervical cancer - Node Zero (SURPEC-N0) 早期宫颈癌的手术路径及病理危险因素-淋巴结零(SURPEC-N0)

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.10

T. Shylasree, Stuti Gupta, A. Patil, Pooja Singh, A. Maheshwari, S. Menon, S. Chopra, L. Gurram, P. Popat, U. Mahantshetty, R. Kerkar

{"title":"Surgical route and pathological risk factors in early cervical cancer - Node Zero (SURPEC-N0)","authors":"T. Shylasree, Stuti Gupta, A. Patil, Pooja Singh, A. Maheshwari, S. Menon, S. Chopra, L. Gurram, P. Popat, U. Mahantshetty, R. Kerkar","doi":"10.20517/2394-4722.2022.10","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.10","url":null,"abstract":"Aim: The aim of this study is to compare disease-free survival (DFS) and overall survival (OS) in patients with stage I cervical cancer (≤ 4cms, lymph node-negative) undergoing open radical hysterectomy (ORH) vs. minimally invasive radical hysterectomy (MIRH). Methods: All patients undergoing radical hysterectomy between January 2012-December 2018 from the largest tertiary referral cancer centre were included. A 1:1 propensity matching was done based on four independent prognostic factors to compare DFS and OS with the route of surgery. Results: One hundred and ninety-nine patients were included during the study period. The median age of the cohort was 50 years. The median follow-up of patients was 47 months. Following 1:1 propensity matching, a total of 174 patients were analysed for DFS and OS in ORH (n = 87) and MIRH (n = 87) groups. Protective measure was used in two-thirds of the patients during MIRH. Twenty-nine patients (16.7%) had recurrences. For the matched cohort (n = 174), the DFS at 36 and 60 months was 84.8% (78.1%-89.6%) and 81% (73.4%-86.6%) respectively and the OS was 96.5% (91.7%-98.5%) and 95.6% (90.3%-98%) respectively. There was no statistically significant difference in DFS or OS between ORH and MIRH. Conclusion: The present study showed no difference in oncological outcomes in MIRH compared to ORH. Retrospective audits on patient characteristics such as screening/vaccination history along with surgical technique/load and matching for crucial risk factors should be factored in future studies to eliminate the possible methodological errors.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature 转移性尿路上皮癌预后的决定因素:文献综述

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.04

Gavin Hui, A. Khaki, P. Grivas

{"title":"Determinants of prognosis in metastatic urothelial carcinoma: a review of the literature","authors":"Gavin Hui, A. Khaki, P. Grivas","doi":"10.20517/2394-4722.2022.04","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.04","url":null,"abstract":"The treatments for metastatic urothelial carcinoma (mUC) have advanced substantially since 2016. Prognostic tools have been used to inform clinical trial designs and treatment decisions. Historically, prognostic tools were developed for mUC based on older clinical trials involving cytotoxic chemotherapy. As novel therapies emerged, there are studies investigating prognostic factors in the era of immune checkpoint inhibitors (ICI), antibody-drug conjugates, and targeted therapies. This review aims to highlight prognostic factors in mUC and their potential in clinical decision-making and research. In the setting of chemotherapy, patient performance status, site of metastatic burden, and specific laboratory findings were found to have prognostic value in mUC. In the era of ICI, newer models identified variables such as neutrophil to lymphocyte ratio, platelet count, and lactate dehydrogenase to also have potential prognostic value. In addition to clinical biomarkers, molecular biomarkers, such as PD-L1 assay and fibroblast growth factor receptor 2 and 3 genomic testings, may have promising prognostic and predictive implications. Current methods of identifying clinical and molecular prognostic factors involve clinician insight. As large complex datasets emerge, machine learning and artificial intelligence may help data analysis and detect important prognostic features. With careful validation, such machine learning-based strategies may help create more robust prognostic and/or predictive models in the future.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67651979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Radiomics in sarcoma trials: a complement to RECIST for patient assessment 放射组学在肉瘤试验中的应用:对RECIST患者评估的补充

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.57

C. Geady, D. Shultz, A. Razak, S. Schuetze, Benjamin Haibe-Kains

{"title":"Radiomics in sarcoma trials: a complement to RECIST for patient assessment","authors":"C. Geady, D. Shultz, A. Razak, S. Schuetze, Benjamin Haibe-Kains","doi":"10.20517/2394-4722.2022.57","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.57","url":null,"abstract":"Radiological imaging has a critical role in the diagnosis of sarcomas and in evaluating therapy response assessment. The current gold standard for response assessment in solid tumors is the Response Evaluation Criteria in Solid Tumors, which evaluates changes in tumor size as a surrogate endpoint for therapeutic efficacy. However, tumors may undergo necrosis, changes in vascularization or become cystic in response to therapy, with no significant volume changes; thus, size assessments alone may not be adequate. Such morphological changes may give rise to radiographic phenotypes that are not easily detected by human operators. Fortunately, recent advances in high-performance computing and machine learning algorithms have enabled deep analysis of radiological images to extract features that can provide richer information about intensity, shape, size or volume, and texture of tumor phenotypes. There is growing evidence to suggest that these image-derived or “radiomic features” are sensitive to biological processes such as necrosis and glucose metabolism. Thus, radiomics could prove to be a critical tool for assessing treatment response and may present an integral complement to existing response criteria, opening new avenues for patient assessment in sarcoma trials.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The peripheral T-cell lymphoma: can we pivot from the chemotherapy-predicated paradigm? 外周t细胞淋巴瘤:我们能否从化疗预测范式转向?

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.17

Helen Ma, E. Marchi

引用次数: 0

Sensitivity of MCF-7 mammosphere CSCs to neutron radiation MCF-7乳球csc对中子辐射的敏感性

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.29

V. Shuvatova, Y. Semochkina, A. Strepetov, E. Moskaleva

{"title":"Sensitivity of MCF-7 mammosphere CSCs to neutron radiation","authors":"V. Shuvatova, Y. Semochkina, A. Strepetov, E. Moskaleva","doi":"10.20517/2394-4722.2022.29","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.29","url":null,"abstract":"Aim: Cancer stem cells (CSCs) are highly resistant to chemotherapy and γ-irradiation. Neutrons have a high linear energy transfer, which can lead to extensive damage to the DNA of tumor cells and CSCs. The aim of this work was to compare the sensitivity of MCF-7 human breast adenocarcinoma cells and CSCs to γ- and γ,n-irradiation. Methods: To increase the number of CSCs, MCF-7 cells were cultured as mammospheres. γ-irradiation was carried out in a GUT-200M device (60Co source) in the dose range of 1-8 Gy at a dose rate of 0.75 Gy/min. γ,n-irradiation was carried out in an IR-8 reactor in the dose range of 0.05-2 Gy at a dose rate of 0.06 Gy/min. DNA DSB formation was assessed by the level of γH2AX foci using fluorescence microscopy and flow cytometry. CSCs were identified by flow cytometry as CD44+/CD24-/low cells. Results: We showed that γ,n-irradiation induced the formation of γH2AX foci of a larger size than did γ-irradiation and led to more severe DNA damage per 1 Gy. Moreover, γ,n-radiation was found to have a high relative biological effectiveness (RBE) as assessed by the cell survival rate, the number of CSCs in culture, and the ability of CSCs to repopulate. The highest RBE of neutron radiation was observed at low doses, when cell survival rate decreased by only 5%-10%. With an increase in the radiation dose, the RBE value decreased for all studied parameters, but it remained as high as 5. Conclusion: γ,n-radiation is highly effective against CSCs. Our results explain the efficacy of neutron therapy for resistant forms of breast cancer.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers for therapy selection in metastatic urothelial cancer 转移性尿路上皮癌治疗选择的生物标志物

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.171

T. Jun, J. Anker, M. Galsky

引用次数: 4

Reactive oxygen species in the progression and treatment of malignant mesothelioma 活性氧在恶性间皮瘤进展和治疗中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.41

Ava Cote, T. Messier, B. Cunniff

{"title":"Reactive oxygen species in the progression and treatment of malignant mesothelioma","authors":"Ava Cote, T. Messier, B. Cunniff","doi":"10.20517/2394-4722.2022.41","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.41","url":null,"abstract":"Malignant mesothelioma (MM) is an aggressive cancer that affects the pleural and peritoneal mesothelial lining of the lungs and abdomen. Survival rates for patients with MM remain extremely low and effective treatments are limited. MM tumors harbor both genotypic and phenotypic features that indicate MM tumor cells are under increased oxidative stress, similar to other aggressive cancers. This increased oxidative stress in MM cells supports aggressive growth while providing a therapeutic vulnerability exploitable by redox-modulating compounds. MM tumor cells also exhibit altered mitochondrial structure and function that contribute to the disease through perturbations in metabolism and reactive oxygen species (ROS) production and metabolism. Targeting the altered redox status in cancer through increasing cellular ROS levels directly or inhibiting cellular antioxidant pathways and disrupting ROS scavenging mechanisms has become an exciting area for therapeutic intervention. This review discusses ROS sources and signaling, mitochondrial structure and function and targeting mitochondria ROS as a therapeutic approach for the treatment of MM.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0